|
|
Article: Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder.
- Article from:
- PR Newswire
- Article date:
- May 9, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Four Million Americans are Diagnosed Annually with Generalized Anxiety Disorder
INDIANAPOLIS, May 9 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced the recent submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the treatment of generalized anxiety disorder.
Cymbalta is already approved in the United States for the treatment of major depressive disorder and the management of diabetic peripheral neuropathic pain, both in adults. Lilly is also conducting Phase III studies on Cymbalta and its effects on fibromyalgia, a chronic, often debilitating pain ...